Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00015626 · ClinicalTrials.gov registry record · Phase 2

A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)

A Phase 2 study of Diabetes Mellitus and Insulin Resistance, sponsored by National Center for Research Resources (NCRR).

Completed
Registry status
Phase 2
Development phase
300
Enrollment target
1
Study location

NCT00015626: Completed Phase 2 study of Diabetes Mellitus and Insulin Resistance, sponsored by National Center for Research Resources (NCRR).

NCT00015626 is a Phase 2 study of Diabetes Mellitus and Insulin Resistance that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 300 participants, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00015626, a Phase 2 study of Diabetes Mellitus and Insulin Resistance, has completed, sponsored by National Center for Research Resources (NCRR).

COMPLETED
Registry status
Phase 2
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to aggressively treat insulin resistance and its clinical manifestations when they first appear in childhood, and to prevent the subsequent progression towards impaired glucose tolerance and type-2 diabetes. In the process of this clinical trial, we will learn more about the early manifestations of insulin resistance, its treatment, and its relationship to obesity and type-2 diabetes through parallel in-vivo and in-vitro studies.

Conditions Studied

Diabetes Mellitus Insulin Resistance

Interventions

  • DRUG Metformin
  • PROCEDURE skin biopsy
  • DRUG pioglitazone
  • BEHAVIORAL diet and exercise
  • DRUG rosiglitazone

Study Locations (1)

New York

  • Cornell University - New York

Trial Details

FieldValue
Enrollment Target 300 participants
Phase Phase 2
National Center for Research Resources (NCRR)

94 total trials

What the finished NCT00015626 record still lists

NCT00015626 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (84% lower).

The record links to 2 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 5 interventions - of which Metformin is the first listed.

NCT00015626 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00015626 about?

NCT00015626 is a clinical study titled "A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)". The goal of this study is to aggressively treat insulin resistance and its clinical manifestations when they first appear in childhood, and to prevent the subsequent progression towards impaired glucose tolerance and type-2 diabetes. In the process of this clinical trial, we will learn more about th...

What is the current status of trial NCT00015626?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants.

What conditions does trial NCT00015626 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Insulin Resistance.

What interventions are being tested in trial NCT00015626?

The interventions under investigation include: Metformin (DRUG), skin biopsy (PROCEDURE), pioglitazone (DRUG), diet and exercise (BEHAVIORAL), rosiglitazone (DRUG).

Who is sponsoring clinical trial NCT00015626?

This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00015626 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00015626's enrollment target sits among peer trials

300 66th of 208 higher than 141 of 208 other Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Related registry views

Source: ClinicalTrials.gov NCT00015626, the US trial registry maintained by the National Library of Medicine. NCT00015626 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.